On September 25, Sinopharm's China Biotech mRNA vaccine industrialization base officially started in Jiading, Shanghai.

On September 25, Sinopharm's China Biotech mRNA vaccine industrialization base officially started in Jiading, Shanghai. Photo courtesy of Jiading, Shanghai, The Paper News reporter learned of the above news from the Jiading District Government of Shanghai. This marks the start of Sinopharm's Fu Nuojian mRNA vaccine industrialization project, and it is also Sinopharm's promotion of the development of a new generation of mRNA vaccine products, which will benefit the people's livelihood. Another major milestone. The base is located at No. 2111, Wenbei Road, Nanxiang Town, Jiading District, Shanghai, with a total construction area of more than 30,000 square meters and a production workshop of more than 16,000 square meters. After it is completed and put into production, it will become a domestically leading mRNA vaccine production in terms of design capacity and technology. The workshop meets the requirements of biomedicine automation, informatization, intelligence, and internationalization, and builds a low-carbon, energy-saving, and environmentally friendly modern intelligent mRNA vaccine industrialization base.

Lu Fangzhou, Secretary of the Jiading District Committee, said that to accelerate the implementation of Sinopharm's China Bio-Renovation mRNA technology in Nanxiang, Jiading, vaccine products will be put into production and available as soon as possible, which is a milestone for the construction of the region's biomedical industry cluster. Jiading District will fully support Construction of Sinopharm China Biotech mRNA vaccine industrialization base.

Liu Jingzhen, Chairman of Sinopharm Group, said in a speech that Sinopharm Group attaches great importance to the establishment of a scientific and technological research and industrialization project leadership group headed by Yang Xiaoming, Chairman of Sinopharm Sinopharm Group, to construct the engineering project of Sinopharm Sinopharm's mRNA vaccine. Provide comprehensive support to clinical research, production system, quality system, etc.

Source: The Paper

Disclaimer: Please contact us if it involves content, copyright or other issues.